The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomised double‐blind placebo‐controlled trial
Research output: Contribution to journal › Article › peer-review
Materials and Methods
Design: Double‐blind, randomised, placebo‐controlled pilot trial.
Setting: Mental health centres and primary care within Southern Health NHS Foundation Trust.
Participants: Adults with schizophrenia, schizoaffective, or first‐episode psychosis prescribed antipsychotic medication who were overweight or obese.
Intervention: Once daily subcutaneous liraglutide or placebo, titrated to 3.0 mg daily, for 6 months.
Primary outcome: recruitment, consent, retention and adherence.
Secondary exploratory outcomes: weight, HbA1c and Brief Psychiatric Rating Scale.
Results: 799 individuals were screened for eligibility. The commonest reasons for exclusion were ineligibility (44%) and inability to make contact (28%). The acceptance rate, as a proportion of all eligible participants, was 12.2%. The commonest stated reason why eligible candidates declined to participate related to the study specific medication and protocol (n= 50). 47 participants were randomised with 79% completing the trial. Participants in the liraglutide arm had lost a mean 5.7±7.9 kg compared with no significant weight change in the placebo group (treatment difference −6.0 kg, p=0.015). BMI, waist circumference and HbA1c reduced in the intervention group.
Conclusions: This study supports the need for a larger randomised controlled trial to evaluate use of liraglutide (maximum dose 3.0 mg daily) in the management of obesity in people with severe mental illness.
|Journal||Diabetes, Obesity and Metabolism|
|Early online date||16 Feb 2021|
|Publication status||Early online - 16 Feb 2021|
- The use of liraglutide 3.0 mg daily
Rights statement: This is the peer reviewed version of the following article: Whicher, CA, Price, HC, Phiri, P, et al. The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double‐blind, placebo‐controlled trial. Diabetes Obes Metab. 2021, which has been published in final form at https://doi.org/10.1111/dom.14334. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
Accepted author manuscript (Post-print), 1.6 MB, PDF document
Due to publisher’s copyright restrictions, this document is not freely available to download from this website until: 16/02/22